Literature DB >> 16166422

Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis.

Dipok Kumar Dhar1, Timothy C Wang, Hideki Tabara, Yasuhito Tonomoto, Riruke Maruyama, Mitsuo Tachibana, Hirofumi Kubota, Naofumi Nagasue.   

Abstract

PURPOSE: Trefoil factor family (TFF) peptides are thought to contribute to epithelial protection and restitution by virtue of their protease-resistant nature and their strong affinity for mucins. However, they are often overexpressed in tumors, where they seem to be negative prognostic factors, possibly contributing to tumor spread, although the precise mechanisms have not been defined. EXPERIMENTAL
DESIGN: Tissue sections from 111 patients with curatively resected advanced gastric carcinoma were immunohistochemically stained for TFF2, ITF (TFF3), and CD34. Microvessel density was expressed as number and area of microvessels. Results were correlated with clinicopathological characteristics and patient survival.
RESULTS: Forty-nine (44.1%) and 41 (36.9%) tumors were immunohistochemically positive for TFF3 and TFF2, respectively. Among the various clinicopathologic variables, overexpression of TFF3 had a significant correlation with patient age only. In addition, a significantly higher prevalence of positive TFF2 staining was detected in large, diffuse tumors and in tumors with lymph node metastasis. The number of microvessels had a significant correlation with both TFF3 and TFF2 staining, whereas the area of microvessels had a significant correlation only with TFF3 staining. Both TFF3 and TFF2 were independent predictors of a worse disease-free survival. TFF3 had a gender-specific negative survival advantage, with a 91.3% disease-free survival in female patients with TFF3-negative advanced gastric carcinoma.
CONCLUSIONS: Induction of increased tumor vascularity might be one of the mechanisms by which TFFs confer metastatic phenotype and frequent disease recurrence in gastric carcinomas. Female patients with TFF3-negative advanced gastric carcinoma have comparable survival as that reported for patients with early gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166422     DOI: 10.1158/1078-0432.CCR-05-0671

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

Review 1.  Trefoils: An unexplored natural protective shield of oral cavity.

Authors:  Akanksha Choudhary; C N Smitha; D K Suresh
Journal:  J Oral Biol Craniofac Res       Date:  2015-07-29

2.  Trefoil factor family peptides TFF1 and TFF3 in the nervous tissues of developing mouse embryo.

Authors:  Tatjana Belovari; Nikola Bijelić; Maja Tolušić Levak; Mirela Baus Lončar
Journal:  Bosn J Basic Med Sci       Date:  2015-02-01       Impact factor: 3.363

Review 3.  Structure, Function, and Therapeutic Potential of the Trefoil Factor Family in the Gastrointestinal Tract.

Authors:  Nayara Braga Emidio; Stuart M Brierley; Christina I Schroeder; Markus Muttenthaler
Journal:  ACS Pharmacol Transl Sci       Date:  2020-06-09

4.  Proteomics in gastroparesis: unique and overlapping protein signatures in diabetic and idiopathic gastroparesis.

Authors:  Madhusudan Grover; Surendra Dasari; Cheryl E Bernard; Lakshmikanth L Chikkamenahalli; Katherine P Yates; Pankaj J Pasricha; Irene Sarosiek; Richard McCallum; Kenneth L Koch; Thomas L Abell; Braden Kuo; Robert J Shulman; Simon J Gibbons; Travis J McKenzie; Todd A Kellogg; Michael L Kendrick; James Tonascia; Frank A Hamilton; Henry P Parkman; Gianrico Farrugia
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-09-04       Impact factor: 4.052

5.  Comparison of serum trefoil factor 3 with the pepsinogen test for the screening of diffuse-type gastric cancer.

Authors:  Ju Yup Lee; Kyung Sik Park; Hyun-Gyo Lee; Won-Ki Baek; Kwang Bum Cho; Yoo Jin Lee; Yoon Suk Lee; Seung-Wan Ryu
Journal:  Clin Exp Med       Date:  2016-05-06       Impact factor: 3.984

6.  Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.

Authors:  Nagarajan Kannan; Jian Kang; Xiangjun Kong; Jianzhong Tang; Jo K Perry; Kumarasamypet M Mohankumar; Lance D Miller; Edison T Liu; Hichem C Mertani; Tao Zhu; Prudence M Grandison; Dong-Xu Liu; Peter E Lobie
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

7.  Increased immunoexpression of trefoil factors in salivary gland tumors.

Authors:  Ponlatham Chaiyarit; Poramaporn Klanrit; Pensri Photipakdee; Ajiravudh Subarnbhesaj; Andrew S Giraud
Journal:  Clin Oral Investig       Date:  2014-05       Impact factor: 3.573

8.  Prognostic significance of the co-expression of nucleophosmin and trefoil factor 3 in postoperative gastric cancer patients.

Authors:  Yong Li; Zhenqing Sun; Kewei Liu; Wensheng Qiu; Ruyong Yao; Tongtong Feng; Chao Xin; Lu Yue
Journal:  Mol Clin Oncol       Date:  2014-07-17

9.  Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: serum trefoil factor 3 is a stable biomarker.

Authors:  Mitsuru Kaise; Jun Miwa; Ai Fujimoto; Jun Tashiro; Daisuke Tagami; Hiromi Sano; Yasukazu Ohmoto
Journal:  Gastric Cancer       Date:  2012-08-21       Impact factor: 7.370

10.  Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: influence of tumor histology and relationship to prognosis.

Authors:  Steven F Moss; Jin-Woo Lee; Edmond Sabo; Anna K Rubin; John Rommel; Bruce R Westley; Felicity E B May; John Gao; Patricia A Meitner; Rose Tavares; Murray B Resnick
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.